Geburtshilfe Frauenheilkd 2018; 78(10): 199-200
DOI: 10.1055/s-0038-1671357
Poster
Freitag, 02.11.2018
Gynäkologische Onkologie VIII
Georg Thieme Verlag KG Stuttgart · New York

Prophylactic surgery among germline TP53 mutation carriers in Germany – a multicentric observational study

Authors

  • N Rippinger

    1   University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland

  • MW Haun

    2   University Hospital Heidelberg, Department of General Internal Medicine and Psychosomatics, Heidelberg, Deutschland

  • C Fischer

    3   University Hospital Heidelberg, Institute of Human Genetics, Heidelberg, Deutschland

  • K Rhiem

    4   University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland

  • A Hübbel

    4   University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland

  • S Grill

    5   Klinikum rechts der Isar; Technical University of Munich, Department of Gynaecology and Centre for Hereditary Breast and Ovarian Cancer, Munich, Deutschland

  • M Kiechle

    5   Klinikum rechts der Isar; Technical University of Munich, Department of Gynaecology and Centre for Hereditary Breast and Ovarian Cancer, Munich, Deutschland

  • FW Cremer

    6   SYNLAB Centre for Human Genetics, Mannheim, Deutschland

  • K Kast

    7   Medical Faculty and University Hospital Carl Gustav Carus, Technical University Dresden, Department of Gynaecology and Obstetrics, Dresden, Deutschland
    8   National Center for Tumor Diseases, Partner Site Dresden, Dresden, Deutschland
    9   German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Dresden, Deutschland

  • HP Nguyen

    10   University Hospital of Tuebingen, Institute of Medical Genetics and Applied Genomics, Tuebingen, Deutschland
    11   University of Bochum, Department of Human Genetics, Bochum, Deutschland

  • N Ditsch

    12   Ludwig-Maximilians University, University Hospital of Munich, Department of Gynaecology and Obstetrics, Munich, Deutschland

  • P Kratz

    13   Hannover Medical School, Paediatric Haematology and Oncology, Hannover, Deutschland

  • S Pfister

    14   Hopp Children's Cancer Centre at the NCT Heidelberg (KiTZ), Heidelberg, Deutschland
    15   German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Division of Paediatric Neurooncology, Heidelberg, Deutschland
    16   University Hospital Heidelberg, Department of Paediatric Oncology, Hematology and Immunology, Heidelberg, Deutschland

  • KW Pajtler

    14   Hopp Children's Cancer Centre at the NCT Heidelberg (KiTZ), Heidelberg, Deutschland
    15   German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Division of Paediatric Neurooncology, Heidelberg, Deutschland
    16   University Hospital Heidelberg, Department of Paediatric Oncology, Hematology and Immunology, Heidelberg, Deutschland

  • D Speiser

    17   University Hospital Charité Berlin, Department of Gynaecology and Obstetrics, Berlin, Deutschland

  • S Seitz

    18   University Medical Centre Regensburg, Department of Gynaecology and Obstetrics, Regensburg, Deutschland

  • H Glimm

    19   National Center for Tumor Diseases (NCT), Heidelberg, Deutschland

  • I Maatouk

    2   University Hospital Heidelberg, Department of General Internal Medicine and Psychosomatics, Heidelberg, Deutschland

  • A Hahne

    20   BRCA Network, Hannover, Deutschland

  • C Sutter

    21   University Hospital Heidelberg, Department of Human Genetics, Heidelberg, Deutschland

  • RK Schmutzler

    4   University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland

  • N Dikow

    21   University Hospital Heidelberg, Department of Human Genetics, Heidelberg, Deutschland

  • C Sohn

    1   University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland

  • S Schott

    1   University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
20. September 2018 (online)

Auch verfügbar auf
 

Objective:

Li-Fraumeni syndrome comprises a rare inherited cancer susceptibility disorder caused by germline TP53 variants. It is associated with an increased life-time risk of breast cancer (BC) in up to 79% of female carriers with a mean age of 35 at the time of onset. In healthy mutation carriers, intensified surveillance programs or prophylactic mastectomy (PM) are possible. If unilateral BC occurs, mastectomy, as a radiation-free alternative to lumpectomy, as well as contralateral PM due to an increased contralateral BC risk of up to 31% should be discussed. Data for carriers' perception are missing; this study addresses PM among female TP53 mutation carriers in Germany.

Methods:

A quadruplet questionnaire addressed socio-demographics, cancer history, PM, surgical technique and its satisfaction among TP53 mutation carriers from eleven German centres between December 2016 and January 2018.

Results:

36 out of all 40 female responders, aged 40.8 ± 12.3 had a personal cancer history: 52.5% had single BC while 27.5% had multiple primary tumours including BC and 10% suffered from another solitary cancer. 45% underwent prophylactic surgery of whom 77.7% had a personal BC history. Most (57%) had chosen breast implants. 72% were highly satisfied with PM while more than 55% would re-perform surgery or recommend it to family members.

Perspective:

TP53 mutation carriers may opt for prophylactic mastectomy after a non-directive consultation, which should always account for age, personal and familial cancer history, as well as the counselee's preferences. However, prospective studies evaluating a potential survival benefit are needed for individual risk assessment.